Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My Custom Filters

Publication date

Text availability

Article attribute

Article type

Additional filters

Article Language

Species

Sex

Age

Other

Search Results

238 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Publication Date timeline is not available.
Page 1
CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Marcinek A, Brauchle B, Rohrbacher L, Hänel G, Philipp N, Märkl F, Strzalkowski T, Lacher SM, Udiljak D, Spiekermann K, Theurich S, Kobold S, Kischel R, James JR, Bücklein VL, Subklewe M. Marcinek A, et al. Among authors: spiekermann k. Cancer Immunol Immunother. 2023 Jul;72(7):2499-2512. doi: 10.1007/s00262-023-03439-x. Epub 2023 Apr 11. Cancer Immunol Immunother. 2023. PMID: 37041225 Free PMC article.
Correction to: CD33 BiTE® molecule-mediated immune synapse formation and subsequent T-cell activation is determined by the expression profile of activating and inhibitory checkpoint molecules on AML cells.
Marcinek A, Brauchle B, Rohrbacher L, Hänel G, Philipp N, Märkl F, Strzalkowski T, Lacher SM, Udiljak D, Spiekermann K, Theurich S, Kobold S, Kischel R, James JR, Bücklein VL, Subklewe M. Marcinek A, et al. Among authors: spiekermann k. Cancer Immunol Immunother. 2023 Jul;72(7):2513-2514. doi: 10.1007/s00262-023-03457-9. Cancer Immunol Immunother. 2023. PMID: 37154851 Free PMC article. No abstract available.
[Recurrent hemolysis and iron overload of unclear origin].
Distelmaier L, Gebhard C, Holzäpfel A, von Bergwelt-Baildon M, Theurich S, Cario H, Spiekermann K. Distelmaier L, et al. Among authors: spiekermann k. Inn Med (Heidelb). 2024 Oct 1. doi: 10.1007/s00108-024-01801-4. Online ahead of print. Inn Med (Heidelb). 2024. PMID: 39354234 German.
[Approach to patients with polyglobulia].
Holch J, Spiekermann K. Holch J, et al. Among authors: spiekermann k. MMW Fortschr Med. 2023 Jan;165(1):46-47. doi: 10.1007/s15006-022-2152-9. MMW Fortschr Med. 2023. PMID: 36648673 Review. German. No abstract available.
AGIHO guideline on evidence-based management of COVID-19 in cancer patients: 2022 update on vaccination, pharmacological prophylaxis and therapy in light of the omicron variants.
Giesen N, Busch E, Schalk E, Beutel G, Rüthrich MM, Hentrich M, Hertenstein B, Hirsch HH, Karthaus M, Khodamoradi Y, Koehler P, Krüger W, Koldehoff M, Krause R, Mellinghoff SC, Penack O, Sandherr M, Seggewiss-Bernhardt R, Spiekermann K, Sprute R, Stemler J, Weissinger F, Wörmann B, Wolf HH, Cornely OA, Rieger CT, von Lilienfeld-Toal M. Giesen N, et al. Among authors: spiekermann k. Eur J Cancer. 2023 Mar;181:102-118. doi: 10.1016/j.ejca.2022.11.030. Epub 2022 Dec 10. Eur J Cancer. 2023. PMID: 36652889 Free PMC article. Review.
[Aetiology and diagnostic of leucocytosis].
Ziemann F, Spiekermann K. Ziemann F, et al. Among authors: spiekermann k. MMW Fortschr Med. 2023 Jan;165(1):40-42. doi: 10.1007/s15006-022-2167-2. MMW Fortschr Med. 2023. PMID: 36648671 Review. German. No abstract available.
Improving risk stratification for 2022 European LeukemiaNet favorable-risk patients with acute myeloid leukemia.
Archer KJ, Fu H, Mrózek K, Nicolet D, Mims AS, Uy GL, Stock W, Byrd JC, Hiddemann W, Metzeler KH, Rausch C, Krug U, Sauerland C, Görlich D, Berdel WE, Woermann BJ, Braess J, Spiekermann K, Herold T, Eisfeld AK. Archer KJ, et al. Among authors: spiekermann k. Innovation (Camb). 2024 Oct 21;5(6):100719. doi: 10.1016/j.xinn.2024.100719. eCollection 2024 Nov 4. Innovation (Camb). 2024. PMID: 39529956 Free PMC article.
Evolution of T-cell fitness through AML progression: enhanced bispecific T-cell engager-mediated function of bone marrow T cells at remission compared to initial diagnosis and relapse.
Kazerani M, Marcinek A, Philipp N, Brauchle B, Taylor JJ, Moreno HD, Terrasi A, Tast B, Rohrbacher L, Wang Y, Warm M, Emhardt AJ, Magno G, Spiekermann K, Herold T, Straub T, Theurich S, Schotta G, Kischel R, Bücklein VL, Subklewe M. Kazerani M, et al. Among authors: spiekermann k. Leukemia. 2024 Oct;38(10):2270-2275. doi: 10.1038/s41375-024-02387-4. Epub 2024 Aug 22. Leukemia. 2024. PMID: 39174782 Free PMC article. No abstract available.
238 results